Biomarkers of Disease Progression in Progressive Supranuclear Palsy for Use in Clinical Trials

Overview

Journal Brain Commun

Publisher Oxford University Press

Date 2025 Jan 30

PMID 39882025

Authors

Cassandra Marotta

Benjamin Sinclair

Terence J OBrien

Lucy Vivash

Affiliations

Soon will be listed here.

Abstract

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease with no current disease-modifying treatments approved. Longitudinal research and clinical trials for PSP are ongoing and require reliable measures that are sensitive to disease progression. Despite susceptibility to subjective limitations, clinical and cognitive assessments are the most used instruments in therapeutic trials in PSP. The objective of this review was to identify measures that have been studied longitudinally as measures of progression and are suitable for use as clinical trial endpoints. We reviewed the measures currently used as trial endpoints, identifying the clinical, cognitive, fluid and imaging measures that have previously been studied longitudinally, and discuss current diagnostic and emerging measures that are yet to be studied longitudinally but that may be sensitive to disease progression. We found that many fluid and imaging measures require further research to validate their use as longitudinal measures of change, including emerging measures that have not yet been studied specifically in PSP. We also summarize the sample size estimates required to detect changes in a two-arm, 52-week therapeutic trial and found that specific MRI volumes require the smallest sample sizes to detect change.

References

Golbe L, Ohman-Strickland P . A clinical rating scale for progressive supranuclear palsy. Brain. 2007; 130(Pt 6):1552-65. DOI: 10.1093/brain/awm032. View

Tsai R, Lobach I, Bang J, Whitwell J, Senjem M, Jack Jr C . Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism Relat Disord. 2016; 28:29-35. PMC: 4914401. DOI: 10.1016/j.parkreldis.2016.04.006. View

OSullivan S, Massey L, Williams D, Silveira-Moriyama L, Kempster P, Holton J . Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008; 131(Pt 5):1362-72. DOI: 10.1093/brain/awn065. View

Brittain C, McCarthy A, Irizarry M, McDermott D, Biglan K, Hoglinger G . Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2018; 60:138-145. PMC: 6399076. DOI: 10.1016/j.parkreldis.2018.08.025. View

Gewily M, Plan E, Yousefi E, Konig F, Posch M, Hopfner F . Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory. Mov Disord. 2024; 39(12):2181-2189. PMC: 11657017. DOI: 10.1002/mds.30001. View

Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I . Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2014; 86(3):244-50. PMC: 4256124. DOI: 10.1136/jnnp-2014-308004. View

Guevara C, Bulatova K, Barker G, Gonzalez G, Crossley N, Kempton M . Whole-Brain Atrophy Rate in Idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. Parkinsons Dis. 2016; 2016:9631041. PMC: 4848442. DOI: 10.1155/2016/9631041. View

Schmidli H, Gsteiger S, Roychoudhury S, OHagan A, Spiegelhalter D, Neuenschwander B . Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics. 2014; 70(4):1023-32. DOI: 10.1111/biom.12242. View

Paviour D, Price S, Lees A, Fox N . MRI derived brain atrophy in PSP and MSA-P. Determining sample size to detect treatment effects. J Neurol. 2007; 254(4):478-81. DOI: 10.1007/s00415-006-0396-4. View

10.

Dam T, Boxer A, Golbe L, Hoglinger G, Morris H, Litvan I . Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021; 27(8):1451-1457. DOI: 10.1038/s41591-021-01455-x. View

11.

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

12.

Ashton N, Pascoal T, Karikari T, Benedet A, Lantero-Rodriguez J, Brinkmalm G . Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021; 141(5):709-724. PMC: 8043944. DOI: 10.1007/s00401-021-02275-6. View

13.

Karch C, Jeng A, Goate A . Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J Biol Chem. 2012; 287(51):42751-62. PMC: 3522274. DOI: 10.1074/jbc.M112.380642. View

14.

Chougar L, Arsovic E, Gaurav R, Biondetti E, Faucher A, Valabregue R . Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism. Mov Disord. 2022; 37(6):1245-1255. DOI: 10.1002/mds.28988. View

15.

Paviour D, Price S, Jahanshahi M, Lees A, Fox N . Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain. 2006; 129(Pt 4):1040-9. DOI: 10.1093/brain/awl021. View

16.

Zhang P, Chen J, Cai T, He C, Li Y, Li X . Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders. Front Aging Neurosci. 2022; 14:909552. PMC: 9389149. DOI: 10.3389/fnagi.2022.909552. View

17.

Rojas J, Bang J, Lobach I, Tsai R, Rabinovici G, Miller B . CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2017; 90(4):e273-e281. PMC: 5798651. DOI: 10.1212/WNL.0000000000004859. View

18.

Fouarge E, Monseur A, Boulanger B, Annoussamy M, Seferian A, De Lucia S . Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy. Orphanet J Rare Dis. 2021; 16(1):3. PMC: 7789189. DOI: 10.1186/s13023-020-01663-7. View

19.

Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F . Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012; 69(11):1445-52. DOI: 10.1001/archneurol.2012.1654. View

20.

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson L . Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Mov Disord. 2017; 32(7):995-1005. PMC: 5543934. DOI: 10.1002/mds.27034. View